Molekulargenetik der diabetischen Nephropathie

糖尿病肾病的分子遗传学

• 批准号: 5187914
• 负责人: Professor Dr. Tom H. Lindner
• 金额: --
• 依托单位: Centrum für Thrombose und Hämostase (CTH)
• 依托单位国家: 德国
• 项目类别: Research Grants
• 财政年份: 1999
• 资助国家: 德国
• 起止时间: 1998-12-31 至 2006-12-31
• 项目状态: 已结题
• 来源: https://gepris.dfg.de/gepris/projekt/5187914?language=en
• 关键词: Molekulargenetik; der; diabetischen; Nephropathie

The 4D (Die Deutsche Diabetiker Dialysestudie) Study is a prospective, randomized, double-blind, trial of atorvastatin and placebo in 1200 type 2 diabetic dialysis patients in centers throughout Germany. The study will test the hypothesis that survival on dialysis can be prolonged by atorvastatin treatment. The study is funded, enrollment will begin in early 1998, and anticipated completion will be in 2001. An impressive body of evidence exists supporting the notion that nephropathy is genetically influenced, independent of diabetes; however, information on such genes and their gene loci is scant. We propose to use the unique opportunity provided by the 4D study to test the hypothesis that specific genes, independent of type 2 diabetes, play a role in the susceptibility to diabetic nephropathy. We will recruit all first-degree relatives of patients having siblings, who participate in the 4D study. We will phenotype these relatives in terms of diabetes and nephropathy. We will then evaluate candidate genes and perform a linkage analysis (total genome scan) to identify gene loci relevant to the development of nephropathy. Our findings may elucidate the mechanisms responsible for the commonest cause of end-stage renal disease in Germany.

4D（Die Deutsche Diabetiker Dialysestudie）研究是一项在德国各中心的1200例2型糖尿病透析患者中进行的阿托伐他汀和安慰剂的前瞻性、随机、双盲试验。本研究将检验阿托伐他汀治疗可延长透析生存期的假设。这项研究已获得资金，将于1998年初开始招募，预计将于2001年完成。有大量证据支持肾病受遗传影响的观点，与糖尿病无关;然而，关于这些基因及其基因位点的信息很少。我们建议利用4D研究提供的独特机会来验证以下假设：独立于2型糖尿病的特定基因在糖尿病肾病易感性中发挥作用。我们将招募参与4D研究的有兄弟姐妹的患者的所有一级亲属。我们将根据糖尿病和肾病对这些亲属进行表型分析。然后，我们将评估候选基因，并进行连锁分析（全基因组扫描），以确定与肾病发展相关的基因位点。我们的研究结果可能阐明负责终末期肾病在德国最常见的原因的机制。